Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ragweed allergy vaccine sublingual tablet - ALK-Abello

Next Previous
X
Search
Drug Profile

Ragweed allergy vaccine sublingual tablet - ALK-Abello

Alternative Names: ALK Ragweed Tablet; Ambrosia-artemisiifolia-extract-ALK-Abello; MK-3641; Ragweed AIT; Ragweed allergy immunotherapy - ALK-Abello; Ragweed extract - ALK-Abello; Ragwitek; Ragwizax; SCH 039641; SCH 39641; SLITone ULTRA; SLIToneULTRA

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer ALK-Abello; Merck & Co; Syneos Health
  • Class Allergy immunotherapies; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis
  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 26 Sep 2023 ALK-Abelló completes phase III clinical trials in Allergic rhinoconjunctivitis in Poland, Lithuania, Latvia, France, Estonia and Czechia Republic (Sublingual) (EudraCT2020-000455-12) (NCT04881461)
  • 04 Jun 2021 Phase-III clinical trials in Allergic rhinoconjunctivitis in Latvia, Poland (Sublingual) (NCT04881461)
  • 11 May 2021 ALK-Abello plans the phase III Rhapsody trial for Allergic-rhinoconjunctivitis in France (Sublingual, drops) (NCT04881461)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top